Markus Aebi
Corporate Officer/Principal chez Institute of Microbiology
Postes actifs de Markus Aebi
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Institute of Microbiology | Corporate Officer/Principal | 22/09/2011 | - |
Historique de carrière de Markus Aebi
Anciens postes connus de Markus Aebi
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Swiss National Science Foundation | Corporate Officer/Principal | 01/01/1994 | 01/01/1994 |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Directeur Technique/Scientifique/R&D | 01/05/2010 | - |
| Fondateur | 01/05/2010 | - |
Formation de Markus Aebi
| University of Zurich | Doctorate Degree |
| California Institute of Technology | Undergraduate Degree |
Statistiques
Internationale
| Suisse | 4 |
| Bulgarie | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
| Swiss National Science Foundation |
- Bourse
- Insiders
- Markus Aebi
- Expérience
